Evidence-Based Complementary and Alternative Medicine / 2013 / Article / Tab 2

Research Article

A Metabolomics Profiling Study in Hand-Foot-and-Mouth Disease and Modulated Pathways of Clinical Intervention Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

Table 2

Identified markers between healthy control and HFMD.

ModeR.T (min)Exact massFormula Compound (Resource)Significance/fold change
G2 versus G1G3 versus G2G3 versus G1

1.8145.1103C7H15NO2Acetylcholine (HMDB) **/ 1.48 **/ 0.65 **/ 0.77
2.5202.1205C10H18O4Sebacic acid (HMDB) **/ 1.58 **/ 0.67N.S
2.690.0317C3H6O3Lactic acid (HMDB) **/ 13.4N.S **/ 13.4
3.6258.0141C6H11O9P2-Keto-3-deoxy-6-phosphogluconic acid (HMDB) **/ 5.55 **/ 0.12N.S
3.7247.0246C8H10NO6PPyridoxal phosphate (HMDB) **/ 5.23 **/ 0.31N.S
6.0219.1107C9H17NO5D-Pantothenic acid (HMDB) **/ 0.47 **/ 2.28N.S
6.2138.0429C6H6N2O2Urocanic acid (HMDB) **/ ∞N.S **/ ∞
ESI (+)10.1180.0634C6H12O6beta-D-Glucose (HMDB) **/ 0.38N.S **/ 0.37
13.7519.3325C26H50NO7P1-18:2(9Z,12Z) Lysophosphatidylcholine (HMDB) **/ 0.49 **/ 1.84N.S
12.71169.0504C4H12NO4PPhosphorylcholine (HMDB) **/ 0.13 **/ 5.98N.S
12.72250.1205C14H18O4Ubiquinone (HMDB) **/ 0.27 **/ 0.22 **/ 0.06
14.1671.489C37H70NO7PPhosphatidylethanolamine (KEGG) **/ 0N.S **/ 0
14.3714.5223C47H70O5Diacylglycerol (HMDB) **/ 0N.S **/ 0
14.7571.3638C30H54NO7P1-Acyl-sn-glycerol-3-phosphocholine (HMDB) **/ 2.02 */ 0.88 */ 1.78
16.4103.0997C5H13NOCholine (HMDB) **/ 1.69 **/ 0.69 */ 1.17
17.8522.3604C28H50N4O3SOleic acid (HMDB) **/ 0N.S **/ 0

1.5146.1055C6H14N2O2L-Lysine (HMDB) **/ 1.56 **/ 1.48 **/ 2.02
1.6336.0484C11H15NO9PNicotinate D-ribonucleotide (HMDB) **/ 2.58N.S **/ 2.73
1.8131.0695C4H9N3O2Creatine (HMDB) **/ 0.43 **/ 2.08N.S
2.1119.0582C4H9NO3L-Threonine (HMDB) **/ 0.46 **/ 2.07N.S
4.28366.0577C10H15N4O9PFAICAR (ChemSpider) **/ 16.24 **/ 0.04N.S
4.29104.0473C4H8O3(S)-3-Hydroxy-2-methylpropanoic acid (HMDB) **/ 1.77 **/ 0.54N.S
5.4165.0426C8H7NO32-(Formylamino)-benzoic acid (HMDB) */ 2.08 **/ 0.35N.S
5.6180.0786C10H12O3Coniferyl alcohol (HMDB) **/ ∞ **/ 0N.S
ESI (−)6.5258.1106C8H21NO6Psn-glycero-3-Phosphocholine (HMDB) **/ 0.26 */ 7.93N.S
8.0248.1161C13H16N2O36-Hydroxymelatonin (ChemSpider) **/ 0.18 */ 4.25N.S
10.0276.1321 C11H20N2O6Saccharopine (HMDB) **/ ∞ **/ 0.24 **/ ∞
10.8324.0359C9H13N2O9PPseudouridylic acid (ChemSpider) **/ ∞ **/ 0N.S
12.8308.041C9H13N2O8PdUMP (HMDB) **/ 26.7 **/ 0.1 */ 46.8
15.0364.2613C22H36O4Prostaglandin E2 (HMDB) **/ 2.10N.S **/ 1.83
16.6226.1933C14H26O29Z-Tetradecenoic acid (HMDB) **/ 0.49N.S **/ 0.47

G1: healthy control group; G2: HFMD group; G3: combination therapy group; HMDB: Human Metabolome Database; KEGG: Kyoto Encyclopedia of Genes and Genomes. ( : represented denominator is zero; P < 0.05; P < 0.01; N.S: no significance).